-
Stroke: Antiphospholipid antibodies and ischemic stroke risk.
Time of Update: 2020-10-12
recently published a research paper in the leading journal in the field of cardiovascular disease, a systematic evaluation and meta-analysis designed to assess the association between aPL and RIS.
meta-analysis found that for RIS, the relative risk of aPL was 1.41 (95% CI was 0.91-2.17; I2 was 54%).
-
This "dthyma cancer" will "72 change", 75-year-old grandmother, 45-year-old aunt have been recruited ...
Time of Update: 2020-10-12
After blood testing, Wang grandmother's anti-nuclear antibodies, APS-related antibodies and many other rheumatoid indicators are positive, combined with patients many years ago had a "dry syndrome", has rich clinical experience lin Jin director told Aunt Li: "Your mother is suffering from systemic lupus erythematosus." "" ah?
-
The FDA and EMA have accepted marketing applications for bimekizumab for the treatment of psoriasis.
Time of Update: 2020-10-11
"After a series of positive Phase III data, we are pleased to announce that the FDA and EMA have accepted our application to use bimekizumab as a potential new treatment for psoriasis," said Emmanuel Caeymaex, executive vice president of UMB at UCB.
-
Rheumatology: Risk of severe infection in patients with rheumatoid arthritis who receive JAK inhibitors.
Time of Update: 2020-10-11
This systematic literature review and meta-analysis is designed to assess the risk of severe infection (SI) and shingles (HZ) in patients with rheumatoid arthritis receiving JAK inhibitors, the results of which are published online in Rheaology.
-
Lilly says the new coronavirus combination therapy with antibodies is the main endpoint.
Time of Update: 2020-10-10
On October 8th Regency announced that its global partner, Eli Lilly and Company, had released positive in-period data for the treatment of newly diagnosed patients with mild and moderate coronary pneumonia (COVID-19) in combination with antibodies JS016 (LY-CoV016) and LY-CoV555.
-
Science: The cGAS suppression mechanism that structurally reveals the dependence of nuclear small bodies.
Time of Update: 2020-10-07
September 16, 2020 /--- In a new study, researchers at the University of North Carolina at Chapel Hill identified for the first time a high-resolution structure in the innate immune system in which a key DNA-sensing protein called cGAS binds to a nucleus, the most important UNIT of DNA packaging in the nucleus.
-
Nat Cell Biol: Editing the immune response using CRISPR makes gene therapy more effective.
Time of Update: 2020-10-07
the main goal of this study is to develop CRISPR-based tools to treat inflammatory diseases," said Farzaneh Moghadam, ph.D. student at Kiani Labs and lead author of the paper.
-
Anti-inflammatory drugs may shorten the recovery time of COVID19 patients.
Time of Update: 2020-10-07
September 16, 2020 /--- -- Lilly Pharmaceuticals Inc. said it will shorten its recovery time by adding anti-inflammatory drugs to drugs in hospitalized COVID-19 patients.
study participants were treated with remdesivir, a drug previously shown to shorten recovery time.
-
Nat Immunol: A serious viral infection may "overwhelm" the body's immune cells.
Time of Update: 2020-10-07
September 16, 2020 // -- In a recent study published in the international journal Nature Immunology, scientists from the University of Melbourne and other institutions identified a special mechanism t
-
JAAD: Immunosuppressive drugs do not increase the risk of COVID19 infection.
Time of Update: 2020-10-07
the main findings of their analysis: 36 percent of the 213 patients tested positive for COVID-19, and were more likely to be hospitalized or use a ventilator than the general population.
-
Nat Med: Monoclonal antibody therapy may be expected to help treat COVID-19.
Time of Update: 2020-10-07
paper, researchers reveal how they used this fast-track antibody discovery platform to isolate hundreds of human monoclonal antibodies that protect against surface prick proteins (S) that promote SARS-CoV-2 infections in lung cells.
-
Cell: For the first time in the world, the battle between the puff macrophages and bacteria is revealed in real time.
Time of Update: 2020-10-07
September 16, 2020 /--- In a new study, researchers from the University of Calgary in Canada have discovered how to capture "live" images of immune cells in the lungs.
Cell, 2020, doi:10.1016/j.cell.2020.08.020.2.Researchers discover how to capture images of cells work at inside our lungs.
-
Reducing patient hospitalization Lilly announces preliminary clinical trial results for new coronal and antibody.
Time of Update: 2020-10-07
Today, Eli Lily and Company announced the concept validation data obtained in the mid-term analysis of the BLAZE-1 clinical trial of the new coronavirus and antibody LY-CoV555, developed jointly with AbCellera.
-
Nat Cancer: New immunotherapy is effective in treating cancer.
Time of Update: 2020-10-07
.com Source: Novel immune-oncology approach for potential cancer treatment Original source: A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response, Nature Cancer (2020).
-
New drug for secondary immunodeficiency (SID)! Takeda HyQiva has been approved by the European Union to update the label: for adults, adolescents, children!
Time of Update: 2020-10-07
September 16, 2020 // -- Takeda recently announced that the European Commission (EC) has approved The HyQvia (Human Normal Immunoglobulin (10%), Recombinant Human Hyalurase) label update to expand its use, making it the first and only easy-to-use subsurface immunoglobulin replacement therapy for the treatment of a wider group of patients with secondary immunodeficiency (SID), including adults, adolescents and children.
-
Sci Immunol: Special immune molecular signals may promote the host body's antibody-dependent cytotoxic response to herpes simplex virus.
Time of Update: 2020-10-07
Natural infections in the body mainly cause the production of neutral antibodies targeting gD, but sub-unit protein vaccines designed to induce this reaction have now failed in clinical development; The researchers conducted these studies to test the hypothesis that gD interferes with ADCC through the involvement of HVEM, compared to wild controlled mice, by mediating the cytototoxic effects of antibody dependence (ADCC) by activating the expression of Fc gamma subjects (Fc-Rs).
-
PNAS: The absence of special kinases in the liver may induce type 2 diabetes.
Time of Update: 2020-10-07
Photo Source: CC0 Public Domain Researchers say SphK2 enzymes are important for the body's blood sugar regulation process, and after studying mouse models, the researchers found that the absence of SphK2 enzymes in the liver promotes the accumulation of the fat product statins, thereby impairing insulin function in the liver.
-
Nature Sub-Journal: Revealing new mechanisms for coronavirus to intercept host cells to make viruses is expected to help develop new therapies and vaccines.
Time of Update: 2020-10-07
September 16, 2020 // -- In a recent study published in the international journal Nature Structural and Molecular Biology, scientists from the Federal Institute of Technology in Zurich and others reve
-
New drug for multiple sclerosis! Novarous Kesimpta is fdatic: the first B-cell therapy to be injected once a month at home!
Time of Update: 2020-10-07
Kesimpta is a new targeted B-cell therapy that shows very high efficacy and similar safety compared to the oral drug Aubagio (teriflunomide) and will be the preferred treatment for a wide range of RMS patients.
-
Innovative drug for eosinophilic esophitis! FDA Grants Sanofi/Regenerative Dupixent Breakthrough Drug Qualification: Phase III Clinical Efficacy Significant!
Time of Update: 2020-10-07
!-- Webeditor: page title -- Sanofi and partner Regeneron recently jointly announced that the U.S. Food and Drug Administration (FDA) has Awarded the breakthrough drug qualification (BTD) for the new anti-inflammatory drug Dupixent (Chinese commodity name: Dabito, generic name: Dupilumab) for the treatment of patients with 12-year-old eosinophilic esophitis (EoE).